Drug Trial Radar · NCT07032038
First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Sep 2027
Primary completion
May 2029
Study completion Aug 2029
Sponsor
- Lead sponsor
- Rinri TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- King's College London
- First posted
- Jun 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rinri Therapeutics is conducting a clinical trial of a new cell therapy called Rincell-1. Rincell-1 is being developed to treat adults with neural hearing loss, either age related hearing loss or auditory neuropathy, who also meet criteria for a cochlear implant. The goals of this study are: * To learn about the safety profile of Rincell-1, the procedure used to inject it and the medications given to promote the growth of the cells * To evaluate how well Rincell-1 works by measuring changes in the function of auditory neurons. * To understand if Rincell-1 can be easily and successfully given at the same time as cochlear implant surgery Participants will be randomly assigned to one of two groups: one group that receives a standard care cochlear implant, and the other that will receive an injection of Rincell-1 at the same time as their standard care cochlear implant. Researchers will compare the safety of Rincell-1 in combination with a cochlear implant to a cochlear implant on its own. Participants will take part in the trial for 52 weeks after CI surgery. During that time, they will have regular follow-ups and will take daily measurements at home of their hearing health.
Conditions
- Sensorineural Hearing Loss
- Presbyacusis
- Auditory Neuropathy
Interventions
Otic neural progenitorsDrug
Advanced Cell Therapy - tissue engineered product
cochlear implantationDevice
cochlear implant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of AEsTime frame: From baseline (at screening) to 52 weeks post-implantation
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University Hospitals Birmingham
Birmingham, United Kingdom
Cambridge University Hospital
Cambridge, United Kingdom
Guy's and St Thomas' Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.